Dopamine agonists, dopplers and doubt: Cabergoline-associated cardiac valvulopathy

Internal Medicine Journal

Volumn 39, Issue 4, 2009, Pages 213-215

  Pullan, P T ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PERGOLIDE; QUINAGOLIDE;

AORTA VALVE DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDITORIAL; HEART MUSCLE FIBROSIS; HUMAN; HYPERPROLACTINEMIA; LUNG FIBROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; MALE; PARKINSON DISEASE; PERGOLIDE; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2B;

EID: 65349170900     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01916.x     Document Type: Editorial

References (10)

1. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 356 : 29 38.
2. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007 356 : 39 46.
3. 2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005 513 : 225 8.
4. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006 28 : 1065 78.
5. Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J 2009 39 : 266.
6. Kars M, Delgado V, Holman ER, Feelders RA, Smit JWA, Romijn JA et al. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008 93 : 3348 56. Rapid Electronic Publication first published on Jun 17, 2008 as doi:10.1210/jc.2007-2658.
7. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu M-C, Betea D et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008 159 : 1 5.
8. Delorme S, Serri K, Beauregard C, Mircescu H, Bourdeau I, Houde G et al. Long-term cabergoline therapy and prevalence of valvular heart disease in patients with prolactinomas: preliminary results from a prospective multicenter study. Abstract P3-747, Endocrine Society Congress 2008, San Francisco.
9. Nachtigall LB, Valassi E, McCarty D, Passeri J, Whitely R, Utz A et al. Cardiac valvular function in hyperprolactinemic patients receiving cabergoline. Abstract OR27-2, Endocrine Society Congress 2008, San Francisco.
10. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003 349 : 2023 33.